Relay Therapeutics, Inc. (RLAY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript

Relay Therapeutics said it has strengthened its balance sheet and is preparing to transition toward commercialization following updates across its vascular-anomalies and breast-cancer programs. The company expects regulatory interactions before year-end for its planned frontline breast-cancer Phase III trial, which it intends to initiate in early 2027. Management also said the vascular-anomalies program is progressing rapidly in development.

Analysis

RLAY remains a regulatory-de-risking story rather than a near-term fundamental rerating: the next valuation inflection is whether agency feedback supports a development design capable of producing registrational evidence without a prolonged or enlarged trial. A clean path would lower the probability-weighted time-to-market discount and could expand the multiple before pivotal enrollment begins; ambiguous feedback would expose the stock to a financing-duration debate, regardless of management’s stated commercial ambitions.

The breast-cancer opportunity is competitively differentiated only if mutant-selective PI3K inhibition translates into materially better tolerability and treatment persistence than legacy PI3K approaches. That creates a high bar: Novartis’s established PI3K franchise provides the relevant standard-of-care and commercial benchmark, while any evidence of comparable hyperglycemia, rash, or discontinuation rates would undermine the central premium thesis. The vascular-anomalies program may be strategically more valuable than consensus assigns if it can provide a faster, lower-commercialization-cost proof point, but rarity also limits absolute revenue and makes enrollment and endpoint interpretation important risks.

Near term, conference commentary alone is not a catalyst and should not justify chasing strength. Over the next 1-3 months, the actionable event is the disclosed regulatory update; over 6-18 months, trial design, enrollment velocity, cash burn, and comparative safety will determine whether RLAY becomes a platform-commercialization story or remains a capital-intensive clinical asset. The thesis is falsified by a materially delayed pivotal start, an agency-requested randomized or larger-than-expected program, or guidance implying cash runway does not extend through the next meaningful efficacy readout.

Key Decisions for Investors

• Maintain RLAY as a watch-list long rather than initiate on conference-driven momentum; consider entry only after regulatory feedback confirms pivotal-trial scope and management provides an updated cash-runway bridge. Size as a binary biotech position, with a 3-6 month catalyst horizon.
• For event exposure, prefer a defined-risk call spread expiring after the expected regulatory update rather than outright common stock; the trade requires option-implied volatility and strike pricing before recommendation. Exit if the pivotal-start timeline moves beyond early 2027 or trial requirements materially expand.
• Monitor RLAY versus NVS as a relative clinical-tolerability signal: sustained RLAY outperformance after regulatory clarity is justified only if future data support lower treatment-limiting toxicity, not merely mechanistic selectivity. Avoid treating NVS as a clean short, given its diversified earnings base.
• Set an alert for quarterly operating-cash burn and enrollment guidance. If projected runway falls short of the first pivotal efficacy catalyst, reduce or avoid exposure because financing risk can dominate otherwise favorable regulatory news.